UTHSCSA Faculty Profiles v1.0

Sarantopoulos, John

School of Medicine
Medicine
(210) 450-1785
sarantopoulo@uthscsa.edu

I am a Medical Oncologist caring for adult patients with melanoma and genitourinary (GU) cancers (renal, prostate, and bladder cancers), and a Clinical Investigator with special expertise in antineoplastic drug development. I am a full-time faculty member in the Division of Hematology-Oncology, Department of Medicine, at the Cancer Therapy and Research Center (CTRC) at the University of Texas Health Science Center San Antonio (UTHSCSA), a National Cancer Institute (NCI)-designated Cancer Center. I care for patients in clinics at the CTRC, and at two of our teaching hospitals: University Health System (UHS), and St Lukes Baptist Hospital. I am a lead clinical investigator in one of the three major research programs at the CTRC: The Experimental and Developmental Therapeutics (EDT) Program (a program that translates new knowledge from bench to bedside, and oversees all investigator-initiated clinical trials for cancer). In addition, I am the Leader of the Early-Phase Clinical Disease Site Team at the CTRC, a team that is responsible for the prioritization, conduct, and completion of Phase-I/II Trials at the CTRC. I started my career at the CTRC after completing an advanced training program, the Advanced Drug Development Fellowship Program at the Institute for Drug Development (IDD) at the CTRC. I joined UTHSCSA post merger with the CTRC in Dec 2007. I have been Principal Investigator (PI) or Co-PI in over 75 Phase-I trials including: First-in-Human clinical trials testing new agents for the very first time in human subjects; First-in-Class trials of novel agents that are the first of their kind ever developed for treatment of cancer; Drug-Interaction trials; Food-effect trials studying the effect of a meal on drug absorption and effect; Cardiac-effect trials looking at cardiovascular effects of new anti-cancer agents; and Organ-Dysfunction trials studying the clinical pharmacology of anti-neoplastic drugs in patients with cancer who also have kidney or liver dysfunction. In addition to leading pharmaceutical industry trials, and investigator-initiated trials designed and developed at the CTRC, I have experience leading NCI trials from its Cancer Therapy Evaluation Program (CTEP), its Organ Dysfunction Working Group, and its Cooperative Group, SWOG. I serve on the SWOG Early Therapeutics Committee, overseeing the design and conduct of early-phase trials at the national level. I have also been a co-investigator in over 149 additional early phase clinical trials. In recognition of my contributions to cancer clinical investigations thus far, the NCI awarded its Clinical Investigator Team Leadership Award as a supplement to the CTRC?s Cancer Center Support Grant (CCSG) in 2011 and 2012. I am the first medical oncologist to receive this award at UTHSCSA. In 2013, I was appointed to the NCI Central Institutional Review Board (CIRB) in its inaugural year as an IRB specializing in experimental therapeutics for adults with cancer. I believe that my education, clinical, and research experiences demonstrate that I am part of a select group of physicians that can design, conduct, and complete complex early-phase trials important to the development of new agents for the treatment of cancer. My goals are to lead teams that care for patients with cancer in context of clinical trials as the best option for care; become the Program Director of the Advanced Drug Development Fellowship Program to further mentor young clinical investigators for careers in experimental therapeutics; and to contribute to the national reputation of our Division, and to lead efforts toward our goal of becoming an NCI Comprehensive Cancer Center.

9/2015 - Present Associate Professor University of Texas Health Science Center San Antonio, Cancer Therapy and Research Center, Medicine, San Antonio, TX
9/2015 - Present Interim Director Institute for Drug Development CTRC/UT Health Science Center at San Antonio, Medicine, San Antonio, TX
5/2011 - Present Leader Phase I Experimental Therapeutics University of Texas Health Science Center San Antonio, Cancer Therapy and Research Center, Medicine, San Antonio, TX
1/2011 - Present Leader Melanoma Program CTRC/IDD/UT Health Science Center at San Antonio, Medicine, San Antonio, TX
1/2011 - Present Co-Leader Genitourinary Program CTRC/IDD/UT Health Science Center at San Antonio, Medicine, San Antonio, TX
1/2011 - Present Leader Phase I Experimental Therapeutics CTRC/IDD/UT Health Science Center at San Antonio, Medicine, San Antonio, TX